Cadre (CDRE) Competitors

$29.20 -0.58 (-1.94%)

Closing price 03:59 PM Eastern

Extended Trading

$29.23 +0.03 (+0.10%)

As of 04:10 PM Eastern

CDRE vs. NVST, LIVN, IRTC, MMED, and WRBY

Should you buy Cadre stock or one of its competitors? MarketBeat compares Cadre with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadre include Envista (NVST), LivaNova (LIVN), iRhythm Technologies (IRTC), MiniMed Group (MMED), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does Cadre compare to Envista?

Cadre (NYSE:CDRE) and Envista (NYSE:NVST) are both medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Cadre currently has a consensus target price of $39.75, suggesting a potential upside of 36.12%. Envista has a consensus target price of $28.83, suggesting a potential upside of 24.63%. Given Cadre's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cadre is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cadre has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Envista has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Envista has higher revenue and earnings than Cadre. Cadre is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81
Envista	$2.72B	1.38	$47M	$0.41	56.43

Cadre has a net margin of 5.80% compared to Envista's net margin of 2.41%. Cadre's return on equity of 12.39% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
Envista	2.41%	7.11%	3.91%

44.0% of Cadre shares are held by institutional investors. 30.1% of Cadre shares are held by insiders. Comparatively, 1.0% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cadre had 6 more articles in the media than Envista. MarketBeat recorded 12 mentions for Cadre and 6 mentions for Envista. Envista's average media sentiment score of 0.47 beat Cadre's score of 0.29 indicating that Envista is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envista	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cadre beats Envista on 12 of the 17 factors compared between the two stocks.

How does Cadre compare to LivaNova?

Cadre (NYSE:CDRE) and LivaNova (NASDAQ:LIVN) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

LivaNova has a net margin of 7.48% compared to Cadre's net margin of 5.80%. LivaNova's return on equity of 16.48% beat Cadre's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
LivaNova	7.48%	16.48%	7.59%

In the previous week, Cadre had 10 more articles in the media than LivaNova. MarketBeat recorded 12 mentions for Cadre and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.98 beat Cadre's score of 0.29 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadre has higher earnings, but lower revenue than LivaNova. Cadre is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.04

Cadre currently has a consensus target price of $39.75, suggesting a potential upside of 36.12%. LivaNova has a consensus target price of $77.22, suggesting a potential upside of 6.91%. Given Cadre's higher probable upside, research analysts clearly believe Cadre is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Cadre has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

44.0% of Cadre shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 30.1% of Cadre shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LivaNova beats Cadre on 11 of the 17 factors compared between the two stocks.

How does Cadre compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

iRhythm Technologies presently has a consensus target price of $191.85, suggesting a potential upside of 72.93%. Cadre has a consensus target price of $39.75, suggesting a potential upside of 36.12%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe iRhythm Technologies is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Cadre had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 12 mentions for Cadre and 9 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.34 beat Cadre's score of 0.29 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadre	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadre has a net margin of 5.80% compared to iRhythm Technologies' net margin of -3.53%. Cadre's return on equity of 12.39% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Cadre	5.80%	12.39%	5.08%

44.0% of Cadre shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 30.1% of Cadre shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

iRhythm Technologies has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Cadre has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.88	-$44.55M	-$0.86	N/A
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81

Summary

Cadre beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Cadre compare to MiniMed Group?

Cadre (NYSE:CDRE) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Cadre has higher earnings, but lower revenue than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81
MiniMed Group	$2.99B	1.02	N/A	N/A	N/A

Cadre currently has a consensus target price of $39.75, suggesting a potential upside of 36.12%. MiniMed Group has a consensus target price of $21.67, suggesting a potential upside of 99.14%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Cadre had 9 more articles in the media than MiniMed Group. MarketBeat recorded 12 mentions for Cadre and 3 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.37 beat Cadre's score of 0.29 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadre	Neutral
MiniMed Group	Positive

44.0% of Cadre shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 30.1% of Cadre shares are held by insiders. Comparatively, 2.2% of MiniMed Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cadre has a net margin of 5.80% compared to MiniMed Group's net margin of 0.00%. Cadre's return on equity of 12.39% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
MiniMed Group	N/A	N/A	N/A

Summary

Cadre beats MiniMed Group on 7 of the 12 factors compared between the two stocks.

How does Cadre compare to Warby Parker?

Cadre (NYSE:CDRE) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

44.0% of Cadre shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 30.1% of Cadre shares are owned by insiders. Comparatively, 16.8% of Warby Parker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cadre has higher earnings, but lower revenue than Warby Parker. Cadre is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81
Warby Parker	$871.91M	3.52	$1.64M	$0.02	1,433.05

Cadre presently has a consensus target price of $39.75, suggesting a potential upside of 36.12%. Warby Parker has a consensus target price of $29.00, suggesting a potential upside of 1.18%. Given Cadre's higher probable upside, equities research analysts plainly believe Cadre is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
Warby Parker	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cadre has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

In the previous week, Cadre and Cadre both had 12 articles in the media. Warby Parker's average media sentiment score of 0.34 beat Cadre's score of 0.29 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadre has a net margin of 5.80% compared to Warby Parker's net margin of 0.15%. Cadre's return on equity of 12.39% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
Warby Parker	0.15%	2.30%	1.18%

Summary

Cadre and Warby Parker tied by winning 8 of the 16 factors compared between the two stocks.

Get Cadre News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDRE vs. The Competition

Export

Metric	Cadre	PROTECTION Industry	Industrials Sector	NYSE Exchange
Market Cap	$1.27B	$3.43B	$9.24B	$22.75B
Dividend Yield	1.34%	2.70%	3.59%	4.13%
P/E Ratio	32.81	19.34	25.06	29.86
Price / Sales	2.05	5.06	4,451.16	24.05
Price / Cash	18.52	24.83	27.40	18.80
Price / Book	3.73	3.40	4.79	4.59
Net Income	$44.14M	$106.44M	$794.33M	$1.07B
7 Day Performance	-6.91%	-3.59%	-1.19%	-1.35%
1 Month Performance	-7.08%	-4.89%	0.63%	-1.29%
1 Year Performance	-16.88%	-15.50%	35.48%	21.88%

Cadre Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDRE Cadre	3.9077 of 5 stars	$29.20 -1.9%	$39.75 +36.1%	-15.2%	$1.27B	$610.31M	32.81	2,533
NVST Envista	3.6896 of 5 stars	$24.29 +0.4%	$28.83 +18.7%	+27.4%	$3.95B	$2.72B	59.24	12,000
LIVN LivaNova	2.3367 of 5 stars	$71.75 +2.4%	$77.22 +7.6%	+57.7%	$3.94B	$1.39B	36.79	3,300
IRTC iRhythm Technologies	4.5815 of 5 stars	$118.31 +1.3%	$193.38 +63.5%	-19.1%	$3.89B	$747.14M	N/A	2,400	Positive News Analyst Forecast
MMED MiniMed Group	3.9825 of 5 stars	$11.89 +6.5%	$22.25 +87.1%	N/A	$3.34B	$2.99B	N/A	8,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CDRE) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadre (CDRE) Competitors